{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T18:56:38Z","timestamp":1757703398332},"reference-count":27,"publisher":"Europa Digital & Publishing","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["EuroIntervention"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.4244\/eijv10i6a117","type":"journal-article","created":{"date-parts":[[2014,10,20]],"date-time":"2014-10-20T14:13:37Z","timestamp":1413814417000},"page":"664-671","source":"Crossref","is-referenced-by-count":2,"title":["Clinical outcome following second-generation drug-eluting stent use for off-label versus on-label indications: insights from the two-year outcome of the TWENTE trial"],"prefix":"10.4244","volume":"10","author":[{"given":"Hanim","family":"Sen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming Kai","family":"Lam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth","family":"Tandjung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mounir W.Z.","family":"Basalus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frits H.A.F.","family":"de Man","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Hans W.","family":"Louwerenburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin G.","family":"Stoel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gert K.","family":"van Houwelingen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marije M.","family":"L\u00f6wik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerard C.M.","family":"Linssen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salah A.M.","family":"Sa\u00efd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark B.","family":"Nienhuis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick M.J.","family":"Verhorst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Job","family":"van der Palen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clemens","family":"von Birgelen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2774","reference":[{"key":"key-2014105172222-0","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/s00392-011-0301-8","article-title":"Comparison between on-label versus off-label use of drug-eluting coronary stents in clinical practice: results from the German DES.DE-Registry.","volume":"100","author":"Bauer T.","year":"2011","journal-title":"Clin Res Cardiol."},{"key":"key-2014105172222-1","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.jacc.2007.10.028","article-title":"Off-label use of drug-eluting stents putting it in perspective.","volume":"51","author":"Grines CL.","year":"2008","journal-title":"J Am Coll Cardiol."},{"key":"key-2014105172222-2","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1001\/jama.297.18.1992","article-title":"Outcomes and complications associated with off-label and untested use of drug-eluting stents.","volume":"297","author":"Beohar N.","year":"2007","journal-title":"JAMA."},{"key":"key-2014105172222-3","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1001\/jama.297.18.2001","article-title":"Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents.","volume":"297","author":"Win HK.","year":"2007","journal-title":"JAMA."},{"key":"key-2014105172222-4","doi-asserted-by":"publisher","first-page":"157","DOI":"10.4244\/EIJV5I1A24","article-title":"Coating irregularities of durable polymer-based drug-eluting stents as assessed by scanning electron microscopy.","volume":"5","author":"Basalus MW.","year":"2009","journal-title":"EuroIntervention."},{"key":"key-2014105172222-5","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1056\/NEJMoa1004130","article-title":"Comparison of zotarolimus-eluting and everolimus-eluting coronary stents.","volume":"363","author":"Serruys PW.","year":"2010","journal-title":"N Engl J Med."},{"key":"key-2014105172222-6","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1016\/j.jacc.2012.01.008","article-title":"A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in real-world patients: the TWENTE trial.","volume":"59","author":"von Birgelen C.","year":"2012","journal-title":"J Am Coll Cardiol."},{"key":"key-2014105172222-7","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1016\/j.jcin.2009.09.014","article-title":"Clinical outcomes after unrestricted implantation of everolimus-eluting stents.","volume":"2","author":"Latib A.","year":"2009","journal-title":"JACC Cardiovasc Interv."},{"key":"key-2014105172222-8","first-page":"251","article-title":"Unrestricted use of endeavor resolute zotarolimus-eluting stent in daily clinical practice: a prospective registry.","volume":"24","author":"Galasso G.","year":"2012","journal-title":"J Invasive Cardiol."},{"key":"key-2014105172222-9","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/ccd.23046","article-title":"Resolute Italian study in all comers: immediate and one-year outcomes.","volume":"79","author":"Romagnoli E.","year":"2012","journal-title":"Catheter Cardiovasc Interv."},{"key":"key-2014105172222-10","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1016\/j.jacc.2011.01.036","article-title":"The impact of patient and lesion complexity on clinical and angiographic outcomes after revascularization with zotarolimus- and everolimus-eluting stents: a substudy of the RESOLUTE All Comers Trial (a randomized comparison of a zotarolimus-eluting stent with an everolimus-eluting stent for percutaneous coronary intervention).","volume":"57","author":"Stefanini GG.","year":"2011","journal-title":"J Am Coll Cardiol."},{"key":"key-2014105172222-11","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1016\/j.jacc.2013.04.005","article-title":"Clinical outcome following stringent discontinuation of dual antiplatelet therapy after 12 months in real-world patients treated with second-generation zotarolimus-eluting Resolute and everolimus-eluting Xience V stents: 2-year follow-up of the randomized TWENTE trial.","volume":"61","author":"Tandjung K.","year":"2013","journal-title":"J Am Coll Cardiol."},{"key":"key-2014105172222-12","doi-asserted-by":"publisher","first-page":"664","DOI":"10.4244\/EIJV8I6A104","article-title":"Comparison of eligible non-enrolled patients and the randomised TWENTE trial population treated with Resolute and Xience V drug-eluting stents.","volume":"8","author":"Sen H.","year":"2012","journal-title":"EuroIntervention."},{"key":"key-2014105172222-13","doi-asserted-by":"publisher","first-page":"871","DOI":"10.4244\/EIJV5I7A146","article-title":"Myocardial infarction adjudication in contemporary all-comer stent trials: balancing sensitivity and specificity. Addendum to the historical MI definitions used in stent studies.","volume":"5","author":"Vranckx P.","year":"2010","journal-title":"EuroIntervention."},{"key":"key-2014105172222-14","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","article-title":"Clinical end points in coronary stent trials: a case for standardized definitions.","volume":"115","author":"Cutlip DE.","year":"2007","journal-title":"Circulation."},{"key":"key-2014105172222-15","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1056\/NEJMra0912134","article-title":"Myocardial infarction due to percutaneous coronary intervention.","volume":"364","author":"Prasad A.","year":"2011","journal-title":"N Engl J Med."},{"key":"key-2014105172222-16","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1097\/MCA.0b013e3282f34220","article-title":"Differential outcomes after sirolimus-eluting stent implantation: comparing on-label versus off-label patients in the \u2018real world\u2019.","volume":"19","author":"Jeremias A.","year":"2008","journal-title":"Coron Artery Dis."},{"key":"key-2014105172222-17","doi-asserted-by":"publisher","first-page":"67","DOI":"10.4244\/EIJV5I1A11","article-title":"Expanded use of the TAXUS Express Stent: two-year safety insights from the 7,500 patient ARRIVE Registry programme.","volume":"5","author":"Lasala JM.","year":"2009","journal-title":"EuroIntervention."},{"key":"key-2014105172222-18","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1016\/j.jacc.2013.07.044","article-title":"Zotarolimus- versus everolimus-eluting stents for unprotected left main coronary artery disease.","volume":"62","author":"Mehilli J.","year":"2013","journal-title":"J Am Coll Cardiol."},{"key":"key-2014105172222-19","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/S0140-6736(11)61672-3","article-title":"Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial.","volume":"378","author":"Stefanini GG.","year":"2011","journal-title":"Lancet."},{"key":"key-2014105172222-20","doi-asserted-by":"publisher","first-page":"109","DOI":"10.4244\/EIJV8I1A17","article-title":"Clinical performance of a drug-eluting stent with a biodegradable polymer in an unselected patient population: the NOBORI 2 study.","volume":"8","author":"Danzi GB.","year":"2012","journal-title":"EuroIntervention."},{"key":"key-2014105172222-21","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1002\/ccd.21345","article-title":"Prognostic value of troponin after elective percutaneous coronary intervention: a meta-analysis.","volume":"71","author":"Nienhuis MB.","year":"2008","journal-title":"Catheter Cardiovasc Interv."},{"key":"key-2014105172222-22","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1016\/j.jacc.2006.04.102","article-title":"Isolated elevation in troponin T after percutaneous coronary intervention is associated with higher long-term mortality.","volume":"48","author":"Prasad A.","year":"2006","journal-title":"J Am Coll Cardiol."},{"key":"key-2014105172222-23","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1016\/S0735-1097(03)01044-1","article-title":"Mortality risk conferred by small elevations of creatine kinase-MB isoenzyme after percutaneous coronary intervention.","volume":"42","author":"Ioannidis JP.","year":"2003","journal-title":"J Am Coll Cardiol."},{"key":"key-2014105172222-24","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1161\/01.CIR.0000028146.71416.2E","article-title":"Death following creatine kinase-MB elevation after coronary intervention: identification of an early risk period: importance of creatine kinase-MB level, completeness of revascularization, ventricular function, and probable benefit of statin therapy.","volume":"106","author":"Ellis SG.","year":"2002","journal-title":"Circulation."},{"key":"key-2014105172222-25","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.jacc.2009.03.063","article-title":"Prognostic significance of periprocedural versus spontaneously occurring myocardial infarction after percutaneous coronary intervention in patients with acute coronary syndromes: an analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial.","volume":"54","author":"Prasad A.","year":"2009","journal-title":"J Am Coll Cardiol."},{"key":"key-2014105172222-26","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1016\/j.jacc.2004.06.051","article-title":"Differential mortality risk of postprocedural creatine kinase-MB elevation following successful versus unsuccessful stent procedures.","volume":"44","author":"Jeremias A.","year":"2004","journal-title":"J Am Coll Cardiol."}],"container-title":["EuroIntervention"],"original-title":[],"deposited":{"date-parts":[[2014,10,20]],"date-time":"2014-10-20T14:13:48Z","timestamp":1413814428000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.pcronline.com\/eurointervention\/77th_issue\/117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["EIJV10I6A117"],"URL":"https:\/\/doi.org\/10.4244\/eijv10i6a117","relation":{},"ISSN":["1774-024X"],"issn-type":[{"value":"1774-024X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]}}}